Ampio Pharmaceuticals Inc. (AMPE)

0.4796 +0.0122 (+2.61%)

IEX Real-Time Price

9:31:36 AM EST.

NYSE American : Healthcare

Prev Close 0.4674

Price Open 0.4689

Volume: 145,985

Avg Volume: 2.93M

Market Cap: 51.1M

P/E Ratio -

52 Wk Range 0.3511-4.9499



AMPE Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
83.82M
16.56M
18.14
19.75%

2018-07-13
83.82M
14.98M
13.74
17.87%

2018-06-29
83.82M
14.75M
14.76
17.60%

2018-06-15
83.82M
10.56M
18.09
12.59%




AMPE Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-04-05
Q4 2017
N/A
0.00 (0)
0.00
0.00

2018-03-29
Q4 2017
N/A
0.00 (0)
0.00
0.00

2018-03-22
Q4 2017
N/A
0.00 (0)
0.00
0.00

2018-03-15
Q4 2017
N/A
0.00 (0)
0.00
0.00

News

Biotech Analysis Central Pharma News: Gemphire Pulls Plug, Ampio's FDA Despair, Paratek's Positive FDA Panel (2018-08-13 20:16 SeekingAlpha)

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gemphire Stops Study For treating Pediatric Patients With NASH News: This past Friday, shares of Gemphire Therapeutics ( GEMP ) fell by as much as 75…

 


Statistics

Shares Outstanding: 86.32M

Top 15 Institution Percent: 16.50

Price To Sales: N/A

Price To Book: 21.55

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -219.18

Return On Equity: 1457.07

Profit Margin: N/A

Price History

Beta: 0.62

50-day Moving Avg: 2.08

200-day Moving Avg: 2.39

YTD Change: -86.57

5-day Change: -15.26

1-month Change: -80.03

3-month Change: -81.23

6-month Change: -84.21

1-year Change: 11.29

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Ampio Pharmaceuticals Inc.

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.ampiopharma.com

Ampio Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.